Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Calcitonin During Tirzepatide Therapy

A 76-person observational study found a small early calcitonin rise during tirzepatide therapy, but only two threshold events limited prediction.

Why we wrote this. The paper's prognostic wording can outrun a two-event exploratory analysis, so the denominator and limits need a clear readout.

In this article (5 sections)
  1. How calcitonin was measured
  2. What changed over six months
  3. Why the prognostic result is exploratory
  4. What the study cannot settle
  5. How to read the result

A prospective observational study followed serum calcitonin in 76 adults with obesity during six months of tirzepatide therapy. Median calcitonin rose from 2.05 pg/mL at baseline to 2.12 pg/mL at three months and 2.25 pg/mL at six months[1]. The overall change over time was statistically significant, but the values did not change significantly between months three and six. This small, uncontrolled biomarker study does not establish a monitoring cutoff or show that tirzepatide caused thyroid disease.

The paper appeared online in Obesity Research & Clinical Practice on November 10, 2026. Its purpose was to describe calcitonin over time and explore whether an early change might predict later biochemical behavior[2]. The word "prognostic" needs care here. Only two participants crossed the threshold used in the exploratory analysis, so the result cannot support a clinical prediction rule.

How calcitonin was measured

Investigators enrolled 77 adults with obesity who were starting tirzepatide. One participant was diagnosed with medullary thyroid carcinoma at baseline and was excluded, leaving 76 people for the longitudinal analysis. Serum calcitonin was assessed before therapy, at three months, and at six months. The researchers used nonparametric tests and mixed effects models to evaluate repeated measurements over time[1].

That denominator distinction matters. The baseline diagnosis occurred before longitudinal follow up and should not be counted as a new event during therapy. The abstract does not say that tirzepatide caused it. Nor does the indexed record provide clinical details about that participant, the diagnostic workup, or the relationship between the diagnosis and study enrollment[2].

A prospective design defines measurements before the outcomes are known, which is stronger for timing than a retrospective chart review. It still lacks a control group. Without untreated participants measured on the same schedule, the study cannot separate drug exposure from ordinary biological variation, assay variation, concurrent illness, or other changes during follow up. Mixed effects models can describe repeated values, but they do not create the missing comparator.

What changed over six months

Median calcitonin increased by 0.07 pg/mL from baseline to three months, then by another 0.13 pg/mL by six months. The statistical model found an overall time effect with p less than 0.001. The comparison between three and six months was not statistically significant, with p equal to 0.43[1]. This pattern supports the authors' description of a small early rise followed by stabilization. It does not show that every participant followed the median pattern.

Two participants whose baseline calcitonin was below 12 pg/mL developed values of at least 12 pg/mL during early follow up. No additional threshold crossings occurred at six months[2]. The abstract does not report the exact values for those two people, whether repeat tests confirmed the elevations, or what clinical evaluation followed. A laboratory threshold event is not by itself a cancer diagnosis.

The study also reported median weight loss of 8.3% at three months and 15.0% at six months[1]. Those figures describe the same treated cohort, not a test of whether weight loss produced the calcitonin pattern. The abstract does not present an analysis linking individual weight change to individual calcitonin change. Readers should not infer that losing more weight raised or lowered this biomarker.

Why the prognostic result is exploratory

Early calcitonin change was correlated with change at six months, with a Spearman coefficient of 0.73 and p less than 0.001[2]. A correlation of changes means that participants with a larger early movement tended to have a larger later movement. It does not establish a validated cutoff, and it does not tell clinicians how accurately an early result identifies a future threshold event.

The event count is the key limitation. Prognostic tools normally need enough outcomes to estimate discrimination, calibration, and error with useful precision. Two events are not enough. The authors explicitly called the prognostic analyses exploratory and said that limited follow up plus the small number of events prevented conclusions about cutoffs or monitoring strategies[1].

The association also uses an early version of the same biomarker to anticipate its later change. That can be useful for describing persistence, but it is narrower than predicting a clinical outcome. The study did not report thyroid cancer incidence during follow up as an endpoint. It therefore cannot show that an early calcitonin movement predicts medullary thyroid carcinoma or any other patient outcome.

What the study cannot settle

The public abstract does not state how participants were recruited, how many completed each measurement, or whether any calcitonin values were missing. It does not provide tirzepatide dose histories, concomitant medicines, smoking status, kidney function, laboratory assay details, or adverse event results. Full text was not available through PubMed Central or Europe PMC when this article was prepared, so those details could not be checked independently.

The six month window is too short and the cohort too small to estimate uncommon clinical outcomes, while the absence of an untreated or active comparator means that the observed time pattern remains an association during treatment rather than an estimate of what tirzepatide changed compared with another course of care.

For broader evidence about known risks and reported adverse effects, readers can consult the tirzepatide safety overview. This single paper should not be used to create a personal testing schedule. Its own conclusion rejects that leap. Decisions about symptoms, laboratory testing, or follow up require a qualified healthcare professional who can consider the full clinical context.

How to read the result

The most defensible finding is modest. In 76 analyzed adults, median calcitonin rose slightly during the first three months and showed no significant additional change by month six. Two people crossed the study's laboratory threshold early, leaving too few events to support prediction. The result identifies a question for larger controlled research rather than a new monitoring rule.

Future studies would need a relevant comparison group, longer observation, prespecified clinical endpoints, and transparent accounting for missing measurements. They would also need enough threshold events to test any proposed cutoff in a separate cohort. The tirzepatide research summary can help place this biomarker report beside studies designed to answer efficacy and safety questions. Different designs should not be treated as interchangeable.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

How much did median calcitonin change?

Median calcitonin was 2.05 pg/mL at baseline, 2.12 pg/mL at three months, and 2.25 pg/mL at six months. The study found an overall time effect, with no significant further change from month three to month six.

Did the study establish a calcitonin monitoring cutoff?

No. Only two participants developed new values at or above 12 pg/mL. The authors described the prognostic analysis as exploratory and said the data could not support cutoffs or monitoring strategies.

Does this study show tirzepatide caused thyroid cancer?

No. One participant diagnosed with medullary thyroid carcinoma at baseline was excluded before longitudinal analysis. The remaining study had no untreated comparator and did not report thyroid cancer incidence as a follow up endpoint.

Sources

  1. [1]Angelopoulos et al. Temporal dynamics and prognostic value of serum calcitonin during tirzepatide therapy in adults with obesity. Obes Res Clin Pract. 2026. PMID 43009382.Tier 1 · primary↩
  2. [2]NCBI PubMed EFetch record and structured abstract for PMID 43009382.Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars